ArticleEuropean clinical respiratory journal2026
Patient specific characteristics and risk of iatrogenic pneumothorax after CT-guided biopsy of the lung parenchyma.
Article in European clinical respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ultrasound-based deep learning radiomics for the differential diagnosis of benign and malignant subpleural pulmonary lesions.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: CT-guided transthoracic needle aspiration biopsy (CT-TTNAB) is a cornerstone in diagnosing peripheral lung lesions, but iatrogenic pneumothorax (iPTX) is a common, adverse event. The presence of emphysema is a well-known risk factor but emphysema may vary from light to severe, and discrepancy is important for precise prognostic application. Aim: To validate that decreasing the diffusion capacity of carbon monoxide (DLCO) is a significant risk factor for the development of iPTX and need for insertion of a pleural device. Methods: We conducted a retrospective study of patients undergoing CT-TTNAB for suspected lung cancer between 1 January to 31 December 2023. We recorded age, sex, packyears, performance score (PS), FEV1 (%, categorized), FVC (% of predicted) and DLCO categorized into four groups: >80%, 60-79%, 40-59% and <40% of predicted. Association with iPTX and need for insertion of a pleural device were investigated with multiple logistic regression. Results: Of 328 patients undergoing CT-TTNAB, 160 patients developed iPTX. Multiple logistic regression demonstrated that DLCO < 60% was an independent risk factor for both iPTX (DLCO 40-59%: odds ratio (OR) 2.8; <40%: OR 4.8), and chest tube insertion (OR 5.1, respectively, 15.3). Concerning other variables, only FEV1 30-49% was an independent risk factor (OR 6.5 for chest tube insertion). Conclusion: This study adds novel information to the risk assessment before a CT-TTNAB procedure. We suggest that decreasing DLCO expressed <60%predicted is a clinically meaningful risk factor for both the development of iPTX and need for insertion of a pleural device.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.